Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels.

OBJECTIVES: To determine the efficacy of nicotine patch therapy in adolescents who want to stop smoking and to assess biochemical markers of smoking and nicotine intake. DESIGN: Nonrandomized, open-label trial using a 15 mg/16 h patch. SETTING: Two midwestern cities. SUBJECTS: One hundred one adolescents aged 13 through 17 years smoking at least 10 cigarettes per day (cpd). INTERVENTION: Six weeks of nicotine patch therapy and follow-up visits at 12 weeks and 6 months. MAIN OUTCOME MEASURES: Self-reported smoking abstinence verified by expired-air carbon monoxide (CO) level of no more than 8 ppm, nicotine withdrawal symptoms, and plasma cotinine level. RESULTS: Forty-one participants were female (mean [+/- SD] age, 16.5 [+/- 1.1] years). Median baseline smoking rate was 20.0 cpd (range, 10-40 cpd). Biochemically confirmed point prevalence smoking abstinence was 10.9% (11/101) at 6 weeks and 5.0% (5/101) at 6 months. The mean (+/- SD) plasma cotinine level at baseline was 1510.9 +/- 732.7 nmol/L; for nonsmoking subjects at weeks 3 and 6, 607.8 +/- 386.2 and 710.0 +/- 772.5 nmol/L, respectively. Plasma cotinine levels were correlated with CO levels at baseline (r = 0.27; P = .006), week 3 (r = 0.34; P = .004), and week 6 (r = 0.26; P = .03) and with mean cigarettes smoked per day during weeks 3 (r = 0.24; P = .04) and 6 (r = 0.30; P = .02). Mean smoking rates decreased significantly during the study, an effect that lessened at 12 weeks and 6 months. CONCLUSIONS: Nicotine patch therapy plus minimal behavioral intervention does not appear to be effective for treatment of adolescent smokers. Plasma cotinine and CO levels appear to be valid measures of smoking rates during the cessation process, but not at baseline. Smoking rates were reduced throughout the study. Additional pharmacological and behavioral treatments should be considered in adolescent smokers.

Positive predictive value of clinical suspicion of abdominal aortic aneurysm. Implications for efficient use of abdominal ultrasonography.

Although selective screening for an abdominal aortic aneurysm (AAA) by abdominal palpation aimed at detecting AAAs has engendered considerable support, no population-based data pertaining to the positive predictive value (PPV) of the clinical assessment of AAAs in routine clinical practice are available. Therefore, we used the unique resources of the Rochester (Minn) Epidemiology Project and the Mayo Clinic computerized abdominal ultrasonography database to identify all residents of Olmsted County, Minnesota,who underwent ultrasound examination for a clinically suspected AAA between November 1, 1985, and October 31, 1987. Of 116 residents who were suspected of having an AAA on abdominal palpation and were referred for an ultrasound examination for confirmation, 17 patients had a 3.5-cm or greater AAA by ultrasound examination (PPV = 14.7%). The probability of AAA by ultrasound examination (PPV = 14.7%). The probability of AAA documentation by ultrasound examination given clinical suspicion of an AAA was associated with higher body mass index, older age,and presence of other macrovascular disease. In 17 patients aged 70 years or younger, without other macrovascular disease and with body mass index of 24 or less, only 1 had an AAA of 3.5 cm or greater (PPV = 6%), while 10 of 20 patients aged 70 years or older, with macrovascular disease,and with body mass index greater than 24 had an AAA of 3.5 cm or greater (PPV = 50%). These population-based data that highlight the poor PPV of the clinical assessment for AAAs indicate that abdominal palpation aimed at detecting AAAs as part of a periodic health examination may lead to a much higher rate of false-positive results than indicated by previous referral-based data. Further research is needed to identify patient subgroups in whom abdominal palpation for detection of AAAs will be cost-effective with respect to reduction in AAA mortality.